Kemira Oyj:n puolivuosikatsaus 2019: Vahva tulosparannus jatkui vuoden 2019 toisella neljänneksellä
July 19, 2019 01:30 ET
|
Kemira Oyj
Kemira OyjPuolivuosikatsaus19.7.2019 klo 8.30 Kemira Oyj:n puolivuosikatsaus 2019: Vahva tulosparannus jatkui vuoden 2019 toisella neljänneksellä Tämä on tiivistelmä Kemiran...
Kemira Oyj’s Half-year Financial Report 2019: Strong earnings improvement continued in the second quarter of 2019
July 19, 2019 01:30 ET
|
Kemira Oyj
Kemira OyjHalf-year Financial ReportJuly 19, 2019 at 8.30 am (CET+1) Kemira Oyj’s Half-year Financial Report 2019: Strong earnings improvement continued in the second quarter...
Harrow Health Announces First Quarter 2019 Financial Results
May 09, 2019 16:01 ET
|
Harrow Health, Inc.
SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the first quarter 2019. First Quarter 2019 and Other Recent Notable Highlights: ...
IBT publicerar årsredovisning för 2018
April 04, 2019 14:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) publicerar idag årsredovisningen för räkenskapsåret 2018. Årsredovisningen finns tillgänglig på IBTs hemsida ibtherapeutics.com under avsnittet ”Investerare...
IBT publishes annual report for 2018
April 04, 2019 14:00 ET
|
Infant Bacterial Therapeutics AB
Today, Infant Bacterial Therapeutics AB (publ) publishes the Annual Report for the financial year 2018. The report is available on IBT’s website ibtherapeutics.com under the section “Investors &...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 december 2018
February 08, 2019 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar IBT uppnådde flera viktiga milstolpar under 2018. Dels kontrakterades en CRO (Contract Research Organization) för att utföra den pivotala fas III-studien “The Connection Study”, och...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2018
February 08, 2019 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT reached several significant milestones during 2018. IBT reached agreement with a CRO (Contract Research Organization) to conduct the pivotal Phase III clinical trial, The...
Cellular Biomedicine Group Reports Third Quarter Financial Results and Recent Business Highlights
November 06, 2018 06:56 ET
|
Cellular Biomedicine Group Inc.
Debuted its next 12-18 months’ immuno-oncology clinical development programs for both hematologic malignancies and solid tumors to key opinion leaders, investment and industry executivesLicensed...
Cellular Biomedicine Group Reports Second Quarter and First Half 2018 Financial Results and Business Highlights
August 08, 2018 07:31 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- China Food and Drug Administration (CFDA) Accepts the Company’s Investigational New Drug (IND) Applications for anti-CD19...
Delårsrapport for 1. halvår 2018
August 02, 2018 01:01 ET
|
GreenMobility A/S
Selskabsmeddelelse nr. 9 - 2018København, 2. august 2018 Delårsrapport for 1. halvår 2018 Stærkt første halvår med høj vækst i omsætningen og nye kunder, samt franchiseaftale i Oslo ...